JP2025148452A5 - - Google Patents
Info
- Publication number
- JP2025148452A5 JP2025148452A5 JP2025116414A JP2025116414A JP2025148452A5 JP 2025148452 A5 JP2025148452 A5 JP 2025148452A5 JP 2025116414 A JP2025116414 A JP 2025116414A JP 2025116414 A JP2025116414 A JP 2025116414A JP 2025148452 A5 JP2025148452 A5 JP 2025148452A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence identity
- variable region
- chain variable
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2022/079021 WO2023164872A1 (en) | 2022-03-03 | 2022-03-03 | Anti-cd39 antibodies and use thereof |
| CNPCT/CN2022/079021 | 2022-03-03 | ||
| CN2022126070 | 2022-10-19 | ||
| CNPCT/CN2022/126070 | 2022-10-19 | ||
| PCT/CN2023/079295 WO2023165561A1 (en) | 2022-03-03 | 2023-03-02 | Anti-cd39 antibodies and use thereof |
| JP2024552127A JP7712496B2 (ja) | 2022-03-03 | 2023-03-02 | 抗cd39抗体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552127A Division JP7712496B2 (ja) | 2022-03-03 | 2023-03-02 | 抗cd39抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025148452A JP2025148452A (ja) | 2025-10-07 |
| JP2025148452A5 true JP2025148452A5 (cg-RX-API-DMAC7.html) | 2026-03-06 |
Family
ID=87883061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552127A Active JP7712496B2 (ja) | 2022-03-03 | 2023-03-02 | 抗cd39抗体及びその使用 |
| JP2025116414A Pending JP2025148452A (ja) | 2022-03-03 | 2025-07-10 | 抗cd39抗体及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552127A Active JP7712496B2 (ja) | 2022-03-03 | 2023-03-02 | 抗cd39抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11970543B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486785A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7712496B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240156633A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119173535A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128688A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023227964A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3253669A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002620A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315351A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010646A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340243A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023165561A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260191954A1 (en) * | 2022-12-01 | 2026-07-09 | Innate Pharma | Compositions and methods for neoadjuvant treatment in cancer |
| CN119798442B (zh) * | 2023-12-27 | 2025-12-16 | 华润生物医药有限公司 | 特异性结合cd39的纳米抗体及其用途 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3153526B1 (en) | 2008-01-31 | 2020-09-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| WO2012085132A1 (en) | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
| US10556959B2 (en) * | 2014-11-07 | 2020-02-11 | Xencor, Inc. | Anti-CD39 antibodies and uses thereof |
| EP3380519A1 (en) | 2015-11-23 | 2018-10-03 | Innate Pharma | Cd39 vascular isoform targeting agents |
| WO2017157948A1 (en) | 2016-03-14 | 2017-09-21 | Innate Pharma | Anti-cd39 antibodies |
| US11376269B2 (en) | 2016-05-06 | 2022-07-05 | Inserm | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML) |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| AU2018235092B2 (en) | 2017-03-16 | 2024-09-19 | Innate Pharma | Compositions and methods for treating cancer |
| SG11202000820PA (en) | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| AU2018346447B2 (en) | 2017-10-06 | 2025-06-19 | Innate Pharma | Restoration of T cell activity via the CD39/CD73 axis |
| IL273440B1 (en) | 2017-11-15 | 2026-08-01 | Innate Pharma | Strengthening the effect of ATP release |
| CN113754768B (zh) | 2018-03-14 | 2023-01-06 | 表面肿瘤学公司 | 结合cd39的抗体及其用途 |
| EP3806902A4 (en) | 2018-06-14 | 2022-05-04 | Beth Israel Deaconess Medical Center, Inc. | COMPOSITIONS AND METHODS TO PREVENT OR REVERSE T-CELL DEPLETION BY ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS |
| TWI870353B (zh) | 2018-06-18 | 2025-01-21 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| MX2021010119A (es) | 2019-02-21 | 2021-12-10 | Trishula Therapeutics Inc | Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1. |
| CN114127121B (zh) | 2019-08-12 | 2025-04-11 | 北京恩瑞尼生物科技股份有限公司 | 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物 |
| KR20220050971A (ko) * | 2019-08-27 | 2022-04-25 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | 신규 항-cd39 항체 |
| KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
| CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| US12391756B2 (en) | 2019-11-05 | 2025-08-19 | Jacobio Pharmaceuticals Co., Ltd. | Binding molecule specific for CD39 and use thereof |
| WO2021203058A2 (en) | 2020-04-03 | 2021-10-07 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and adoptive cell therapy |
| US20240052061A1 (en) | 2020-09-10 | 2024-02-15 | Purinomia Biotech, Inc. | Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3 |
| EP4251650A4 (en) | 2020-11-27 | 2024-10-23 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
-
2023
- 2023-03-02 TW TW112107685A patent/TW202340243A/zh unknown
- 2023-03-02 IL IL315351A patent/IL315351A/en unknown
- 2023-03-02 CA CA3253669A patent/CA3253669A1/en active Pending
- 2023-03-02 JP JP2024552127A patent/JP7712496B2/ja active Active
- 2023-03-02 AR ARP230100529A patent/AR128688A1/es unknown
- 2023-03-02 CN CN202380024645.6A patent/CN119173535A/zh active Pending
- 2023-03-02 WO PCT/CN2023/079295 patent/WO2023165561A1/en not_active Ceased
- 2023-03-02 MX MX2024010646A patent/MX2024010646A/es unknown
- 2023-03-02 KR KR1020247032745A patent/KR20240156633A/ko active Pending
- 2023-03-02 EP EP23762959.7A patent/EP4486785A4/en active Pending
- 2023-03-02 US US18/177,729 patent/US11970543B2/en active Active
- 2023-03-02 CN CN202411518282.4A patent/CN119569881B/zh active Active
- 2023-03-02 AU AU2023227964A patent/AU2023227964A1/en active Pending
-
2024
- 2024-03-25 US US18/616,056 patent/US20250084178A1/en active Pending
- 2024-09-02 CL CL2024002620A patent/CL2024002620A1/es unknown
-
2025
- 2025-07-10 JP JP2025116414A patent/JP2025148452A/ja active Pending